Hyponatremia in heart failure: Time for a trial

Journal of Cardiac Failure

Volumn 19, Issue 6, 2013, Pages 398-400

  Goldsmith, Steven R ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEMECLOCYCLINE; LOOP DIURETIC AGENT; OSMOTIC AGENT; PLACEBO; SODIUM; TOLVAPTAN;

CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HOSPITAL READMISSION; HUMAN; HYPONATREMIA; LENGTH OF STAY; MORBIDITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL;

BENZAZEPINES; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 84878534893     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.04.003     Document Type: Editorial

References (15)

1. S.R. Goldsmith Hyponatremia and outcomes in patients with heart failure Heart 98 2012 1761 1762
2. W.T. Abraham, G.C. Fonarow, N.M. Albert, W.G. Stough, M. Gheorghiade, and B.H. Greenberg Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) J Am Coll Cardiol 52 2008 347 356
3. B. Renneboog, W. Musch, X. Vandemergel, M.U. Manto, and G. Decaux Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits Am J Med 119 2006 71 78
4. J. Barsony, M.B. Manigrasso, Q. Xu, H. Tam, and J.G. Verbalis Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats Age (Dordr) 35 2013 271 288
5. G.S. Francis, R.M. Siegel, S.R. Goldsmith, M.T. Olivari, T.B. Levine, and J.N. Cohn Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis Ann Intern Med 103 1985 1 6
6. S.R. Goldsmith, G. Francis, and J.N. Cohn Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure Am J Cardiol 64 1989 1382 1385
7. M. Gheorghiade, G. Filippatos, L.L. De, and J. Burnett Congestion in acute heart failure syndromes: an essential target of evaluation and treatment Am J Med 119 2006 S3 S10
8. J.M. Testani, J. Chen, B.D. McCauley, S.E. Kimmel, and R.P. Shannon Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival Circulation 122 2010 265 272
9. R.W. Schrier, P. Gross, M. Gheorghiade, T. Berl, J.G. Verbalis, and F.S. Czerwiec Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
10. D. Annane, G. Decaux, and N. Smith Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia Am J Med Sci 337 2009 28 36
11. J. Rossi, M. Bayram, J.E. Udelson, D. Lloyd-Jones, K.F. Adams, and C.M. Oconnor Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial Acute Card Care 9 2007 82 86
12. S.E. Lee, D.-J. Choi, C.-H. Yoon, I.-Y. Oh, E.-S. Jeon, and J.-J. Kim Improvement of hyponatremia during hospitalisation for acute heart failure is not associated with improvement of prognosis: an analysis from the Korean Heart Failure (KorHF) registry Heart 98 2012 1798 1804 http://dx.doi.org/10.1136/ heartjnl-2012-302334
13. M. Gheorghiade, J.S. Rossi, W. Cotts, D.D. Shin, A.S. Hellkamp, and I.L. Pina Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial Arch Intern Med 167 2007 1998 2005
14. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1331
15. D.E. Lanfear, H.N. Sabbah, S.R. Goldsmith, S.J. Greene, A.P. Ambrosy, and A.J. Fought Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial Circ Heart Fail 6 2013 47 52